Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells

European Neuropsychopharmacology

Volumn 17, Issue 12, 2007, Pages 768-773

  Tan, Qing Rong ^a   Wang, Xin Zhao ^a   Wang, Chuan Yue ^c   Liu, Xiao Jun ^a   Chen, Yun Chun ^a   Wang, Huai Hai ^a   Zhang, Rui Guo ^a   Zhen, Xue Chu ^d   Tong, Yao ^b   Zhang, Zhang Jin ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

BDNF; c fos; Classical and atypical antipsychotics; Intracellular calcium; PC12 cells; STAT 3

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; ENZYME INHIBITOR; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN C FOS; QUETIAPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RISPERIDONE; ROTENONE; STAT3 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL STRAIN; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; NEUROTOXINS; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROTENONE; STAT3 TRANSCRIPTION FACTOR;

EID: 35348890731     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.03.003     Document Type: Article

References (27)

1. Angelucci F., Mathe A.A., and Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog. Brain Res. 146 (2004) 151-165
2. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., and Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 15 (2005) 311-317
3. Angelucci F., Brene S., and Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10 (2005) 345-352
4. Bai O., Wei Z., Lu W., Bowen R., Keegan D., and Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69 (2002) 278-283
5. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71 (2003) 127-131
6. Bai O., Xu H., and Li X.M. Haloperidol and atypical antipsychotics share a same action of decreasing P75(NTR) mRNA levels in PC12 cells. Life Sci. 79 (2006) 570-574
7. Cosi C., Waget A., Rollet K., Tesori V., and Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 1043 (2005) 32-41
8. Deutch A.Y. Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J. Clin. Psychiatry 55 Suppl B (1994) 37-42
9. Durany N., and Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatr. 19 (2004) 326-337
10. Hashimoto Y., Suzuki H., Aiso S., Niikura T., Nishimoto I., and Matsuoka M. Involvement of tyrosine kinases and STAT3 in humanin-mediated neuroprotection. Life Sci. 77 (2005) 3092-3104
11. Hirsch E.C., Hoglinger G., Rousselet E., Breidert T., Parain K., Feger J., Ruberg M., Prigent A., Cohen-Salmon C., and Launay J.M. Animal models of Parkinson's disease in rodents induced by toxins: an update. J. Neural Transm., Suppl. 65 (2003) 89-100
12. Jann M.W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24 (2004) 1759-1783
13. Maciel E.N., Kowaltowski A.J., Schwalm F.D., Rodrigues J.M., Souza D.O., Vercesi A.E., Wajner M., and Castilho R.F. Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition. J. Neurochem. 90 (2004) 1025-1035
14. Pillai A., Terry Jr. A.V., and Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 82 (2006) 95-106
15. Qing H., Xu H., Wei Z., Gibson K., and Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 17 (2003) 1563-1570
16. Raggi M.A., Mandrioli R., Sabbioni C., and Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr. Med. Chem. 11 (2004) 279-296
17. Schabitz W.R., Kollmar R., Schwaninger M., Juettler E., Bardutzky J., Scholzke M.N., Sommer C., and Schwab S. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34 (2003) 745-751
18. Schubert K.O., Naumann T., Schnell O., Zhi Q., Steup A., Hofmann H.D., and Kirsch M. Activation of STAT3 signaling in axotomized neurons and reactive astrocytes after fimbria-fornix transection. Exp. Brain Res. 165 (2005) 520-531
19. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
20. Stephanou A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 23 (2005) 177-182
21. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., and Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 382 (2005) 27-32
22. Tandon R., and Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. 79 (2005) 145-155
23. Turner B.J., Rembach A., Spark R., Lopes E.C., and Cheema S.S. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J. Neurosci. Res. 74 (2003) 605-613
24. Wang G., Qi C., Fan G.H., Zhou H.Y., and Chen S.D. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett. 579 (2005) 4005-4011
25. Wang H., Xu H., Dyck L.E., and Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 81 (2005) 572-580
26. Wei Z., Bai O., Richardson J.S., Mousseau D.D., and Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73 (2003) 364-368
27. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., and Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J. Neurosci. Res. 74 (2003) 942-947